Últimas noticias sobre VolitionRX (AMEX:VNRX) Bolsa

VolitionRX

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

VolitionRX Ltd

VolitionRx files for common stock, warrants, and units for offering price of $1B

16:11 EST VolitionRx (VNRX) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...

VolitionRx files $100M mixed securities shelf

VolitionRX reports Q3 results

CEO Cameron Reynolds stated, "I am delighted that we have sold more than 110,000 Nu.Q Vet Cancer Tests in the first nine months of 2024; not only i...

VolitionRx reports Q3 revenue up 187% year-over-year to $475K

VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript

VolitionRX Ltd. ( ($VNRX) ) has released its Q3 earnings. Here is a breakdown of the information VolitionRX Ltd. presented to its investors. Voliti...

VolitionRx Posts Strong Q3 Growth and Strategic Advances

Benchmark Co. analyst Bruce Jackson maintained a Hold rating on VolitionRX (VNRX – Research Report) today. The company's shares closed yesterday at...

VolitionRX (VNRX) Gets a Hold from Benchmark Co.

VolitionRx (VNRX) announced that it has entered into definitive agreements for the purchase and sale of (i) 445,648 shares of its common stock to c...

VolitionRx announces pricing of $1.9M registered direct offering

VolitionRx announces pricing of up to $1.9M registered direct offering

VolitionRx (VNRX) announced the results of a large-scale study which shows that its Nu.Q Cancer Test differentiated between malignant and benign pu...

VolitionRx's Nu.Q cancer test shows efficacy in lung cancer detection

VNRX

Press Releases

Volition hosts NETs in sepsis management symposium at ESICM Lives 2024

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Small Cap

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Volition Appoints Timothy I. Still as Chairman

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

Offerings

VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Volition Issues Business Review 2024

Avanos Medical

Bioventus

Cerus

OrthoPediatrics

Innovative Eyewear

Meihua International Medical Technologies Co., Ltd. - Ordinary Shares

Meihua Intl Medical Techs

InspireMD

NexGel

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

Rockwell Medical

Retractable Technologies, Inc. Common Stock

Retractable Technologies

Sanara MedTech

Sharps Technology

TELA Bio

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

WORK Medical Technology Group LTD - Ordinary Shares

WORK Medical Technology

Xtant Medical Holdings, Inc. Common Stock

Comments

VolitionRX

Noticias

Últimas noticias sobre VolitionRX (AMEX:VNRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL